Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives Are Peptides coming off of the FDA Category 2 list? A legal breakdown Holt Law FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of The Peptide Landscape Is Shifting: What Secretary Kennedy's Joe Rogan Interview Could Mean for the Compounding Industry Frier Levitt FDA Peptide Regulation May Shift: What RFK Jr.'s Announcement Means for Compounding FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of